Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.

Enliven Therapeutics Inc.

Enliven Therapeutics, Inc. (($ELVN)) announced an update on their ongoing clinical study. Enliven Therapeutics, Inc. is conducting a Phase 1 clinic...

Current Quarter	$-0.47	Next Quarter	$-0.5
Current Year	$-1.87	Next Year	$-2.19
QoQ Growth	-6.4%	YoY Growth	-17.1%
3Y EPS CAGR	N/A	Target Price	$41.38
Consensus	Buy	Upside	+90.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELVN	$21.75	+2.26%	348.76K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELVN	$21.75	+2.3%	348.76K
3
4
5
6

ELVN

ELVN

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Enliven Therapeutics Inc. Data in Excel

Get Enliven Therapeutics Inc. Data in Excel